The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Recovery, Persistence, and Sequelae in Hepatitis C Virus Infection: A Perspective on Long-Term Outcome
Open accessAbstract
Hepatitis C has emerged in recent years as the most common basis for liver disease in the United States, having infected an estimated 3.9 million people in this country and an estimated 170 million worldwide.Currently, it is the predominant reason for undergoing liver transplantation.The disease it causes is characterized by silent onset in most infected individuals, a high rate of viral persistence, and the potential for development of everworsening chronic liver disease, ranging from chronic hepatitis to cirrhosis and occasionally to hepatocellular carcinoma.Such progression, when it occurs, is also most commonly a silent process that may take 20-40, and occasionally even more, years to reach its end point.Because of these characteristics, it has been exceedingly difficult to accurately assess the natural history.Efforts to accomplish this have consisted of retrospective, prospective, and cohort studies.The most concerning data have derived from the retrospective study approach, generally performed at tertiary referral centers.Because these centers commonly attract persons with existing chronic liver disease, they have tended to describe a high rate of progression to cirrhosis and cancer.This "referral bias" is avoided in the prospective and cohort study approach, and data derived from these studies indicate a lower rate of progression and a correspondingly higher rate of either recovery or minimal liver disease.In this review, we briefly describe potential mechanisms of viral persistence; present detailed information on outcomes that have derived from retrospective, prospective, and cohort studies, involving both adults and children; examine the data regarding progression of fibrosis and of progression to hepatocellular carcinoma; consider cofactors that might enhance liver disease progression; and report the emerging data that suggest that spontaneous viral clearance may be higher than is currently believed.We conclude with the view that severe, life-threatening, progressive liver disease clearly occurs in a sizable minority (perhaps 30%) of chronically infected persons but speculate that fibrosis progression is neither linear or inevitable and hence that most hepatitis C virus carriers will have either a stable nonprogressive course or such indolent pro-Objectives Upon completion of this article, the reader should recognize: 1) the influence of study design on estimates of HCV disease severity; 2) that the rate of spontaneous recovery from HCV infection is higher than previously considered; 3) that fibrosis progression is not linear and is influenced by cofactors, particularly alcohol; 4) that it is likely that the majority of HCV infected individuals will not develop cirrhosis or other life threatening complications of their infection; and 5) that although the individual risk of developing severe complications may be less than 30%, the societal burden of HCV infection is very high because of the high prevalence and global distribution of the agent. AccreditationThe Indiana University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.The Indiana University School of Medicine takes responsibility for the contents, quality, and scientific integrity of this activity. CreditThe Indiana University School of Medicine designates this educational activity for a maximum of 1.0 hours credit toward the AMA Physicians Recognition Award in category one.Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of a cDNA cLone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome
Choo, Q.-L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W., & Houghton, M. (1989) · Science · doi:10.1126/science.2523562 · Cited by 6,875
McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,465
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011
The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994
Alter, M. J., Kruszon-Moran, D., Nainan, O. V., McQuillan, G. M., Gao, F., Moyer, L. A., Kaslow, R. A., & Margolis, H. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908193410802 · Cited by 2,992
The Natural History of Community-Acquired Hepatitis C in the United States
Alter, M. J., Margolis, H. S., Krawczynski, K., Judson, F. N., Mares, A., Alexander, W. J., Hu, P. Y., Miller, J. K., Gerber, M. A., Sampliner, R. E., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272702 · Cited by 1,592
Fattovich, G., Giustina, G., Degos, F., Tremolada, F., Diodati, G., Almasio, P., Nevens, F., Solinas, A., Mura, D., Brouwer, J., et al. (1997) · Gastroenterology · doi:10.1053/gast.1997.v112.pm9024300 · Cited by 1,399
Kiyosawa, K., Sodeyama, T., Tanaka, E., Gibo, Y., Yoshizawa, K., Nakano, Y., Furuta, S., Akahane, Y., Nishioka, K., Purcell, R. H., et al. (1990) · Hepatology · doi:10.1002/hep.1840120409 · Cited by 1,217
Self-citationClinical Outcomes after Transfusion-Associated Hepatitis C
Tong, M. J., El-Farra, N. S., Reikes, A. R., & Co, R. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506013322202 · Cited by 1,198
[Gastric adenocarcinoma and kidney transplantation].
Barrio, J., García-Bengoechea, M., Emparanza, J. I., & Arenas, J. I. (1998) · PubMed · Cited by 1,132
Yoshida, H., Shiratori, Y., Moriyama, M., Arakawa, Y., Ide, T., Sata, M., Inoue, O., Yano, M., Tanaka, M., Fujiyama, S., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-3-199908030-00003 · Cited by 1,096
Clinical Outcomes after Hepatitis C Infection from Contaminated Anti-D Immune Globulin
Kenny-Walsh, E. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904223401602 · Cited by 910
The Outcome of Acute Hepatitis C Predicted by the Evolution of the Viral Quasispecies
Farci, P., Shimoda, A., Coiana, A., Diaz, G., Peddis, G., Melpolder, J. C., Strazzera, A., Chien, D. Y., Munoz, S. J., Balestrieri, A., et al. (2000) · Science · doi:10.1126/science.288.5464.339 · Cited by 884
Self-citationLack of Protective Immunity Against Reinfection with Hepatitis C Virus
Farci, P., Alter, H. J., Govindarajan, S., Wong, D. C., Engle, R., Lesniewski, R. R., Mushahwar, I. K., Desai, S. M., Miller, R. H., Ogata, N., et al. (1992) · Science · doi:10.1126/science.1279801 · Cited by 752
Self-citationBruix, J., Calvet, X., Costa, J., Ventura, M., Bruguera, M., Castillo, R., María Barrera, J., Ercilla, G., María Sanchez-Tapias, J., Vall, M., et al. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91015-5 · Cited by 734
Long-Term Mortality after Transfusion-Associated Non-A, Non-B Hepatitis
Seeff, L. B., Buskell-Bales, Z., Wright, E. C., Durako, S. J., Alter, H. J., Iber, F. L., Hollinger, F. B., Gitnick, G., Knodell, R. G., Perrillo, R. P., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272703 · Cited by 672
Self-citationPREVALENCE OF ANTIBODIES TO HEPATITIS C VIRUS IN ITALIAN PATIENTS WITH HEPATOCELLULAR CARCINOMA
Colombo, M., Choo, Q. L., Del Ninno, E., Dioguardi, N., Kuo, G., Donato, M. F., Tommasini, M. A., & Houghton, M. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91016-7 · Cited by 666
Prognosis of Chronic Hepatitis C: Results of A Large, Prospective Cohort Study
Niederau, C., Lange, S., Heintges, T., Erhardt, A., Buschkamp, M., Hürter, D., Nawrocki, M., Kruska, L., Hensel, F., Petry, W., et al. (1998) · Hepatology · doi:10.1002/hep.510280632 · Cited by 636
Conry-Cantilena, C., VanRaden, M., Gibble, J., Melpolder, J., Shakil, A. O., Viladomiu, L., Cheung, L., DiBisceglie, A., Hoofnagle, J., Shih, J. W., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606273342602 · Cited by 627
Self-citationThe Long–Term Pathological Evolution of Chronic Hepatitis C
Yano, M., Kumada, H., Kage, M., Ikeda, K., Shimamatsu, K., Inoue, O., Hashimoto, E., Lefkowitch, J. H., Ludwig, J., & Okuda, K. (1996) · Hepatology · doi:10.1002/hep.510230607 · Cited by 598
Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis
di Bisceglie, A. M., Goodman, Z. D., Ishak, K. G., Hoofnagle, J. H., Melpolder, J. J., & Alter, H. J. (1991) · Hepatology · doi:10.1002/hep.1840140603 · Cited by 539
Self-citationVogt, M. O., Lang, T., Frösner, G., Klingler, C., Sendl, A., Zeller, A., Wiebecke, B., Langer, B., Meisner, H., & Hess, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909163411202 · Cited by 502
Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features
Dienstag, J. L. (1983) · Gastroenterology · doi:10.1016/0016-5085(83)90336-0 · Cited by 500
Darby, S. C., Ewart, D. W., Giangrande, P. L., Spooner, R. J., Rizza, C. R., Dusheiko, G. M., Lee, C. A., Ludlam, C. A., & Preston, F. E. (1997) · The Lancet · doi:10.1016/s0140-6736(97)05413-5 · Cited by 497
Persistence of Viremia and the Importance of Long–Term Follow–Up After Acute Hepatitis C Infection
Villano, S. A., Vlahov, D., Nelson, K. E., Cohn, S., & Thomas, D. L. (1999) · Hepatology · doi:10.1002/hep.510290311 · Cited by 475
Impact of alcohol on the histological and clinical progression of Hepatitis C infection
Wiley, T. E., McCarthy, M., Breidi, L., McCarthy, M., & Layden, T. J. (1998) · Hepatology · doi:10.1002/hep.510280330 · Cited by 436
TRANSMISSIBLE AGENT IN NON-A, NON-B HEPATITIS
Alter, H., Holland, P., Purcell, R., & Popper, H. (1978) · The Lancet · doi:10.1016/s0140-6736(78)90131-9 · Cited by 424
Self-citationEyster, M. E., Diamondstone, L. S., Lien, J., Ehmann, W. C., Quan, S., & Goedert, J. J. (1993) · PubMed · Cited by 421
Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence
Cerny, A., & Chisari, F. V. (1999) · Hepatology · doi:10.1002/hep.510300312 · Cited by 410
Shimizu, Y. K., Hijikata, M., Iwamoto, A., Alter, H. J., Purcell, R. H., & Yoshikura, H. (1994) · Journal of Virology · doi:10.1128/jvi.68.3.1494-1500.1994 · Cited by 405
Self-citationDeterminants of outcome of compensated hepatitis C virus-related cirrhosis
Serfaty, L., Aumaître, H., Chazouillères, O., Bonnand, A.-M., Rosmorduc, O., Poupon, R. E., & Poupon, R. Y. (1998) · Hepatology · doi:10.1002/hep.510270535 · Cited by 403
Bjoro, K., Froland, S. S., Yun, Z., Samdal, H. H., & Haaland, T. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412153312402 · Cited by 370
45-Year Follow-up of Hepatitis C Virus Infection in Healthy Young Adults
Seeff, L. B., Miller, R. N., Rabkin, C. S., Buskell-Bales, Z., Straley-Eason, K. D., Smoak, B. L., Johnson, L. D., Lee, S. R., & Kaplan, E. L. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-2-200001180-00003 · Cited by 347
Self-citationRosa, D., Campagnoli, S., Moretto, C., Guenzi, E., Cousens, L., Chin, M., Dong, C., Weiner, A. J., Lau, J. Y., Choo, Q. L., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.5.1759 · Cited by 344
Weiner, A., Erickson, A. L., Kansopon, J., Crawford, K., Muchmore, E., Hughes, A. L., Houghton, M., & Walker, C. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.2755 · Cited by 334
Factors predictive of a beneficial response to therapy of hepatitis C
Davis, G. L., & Lau, J. Y. (1997) · Hepatology · doi:10.1002/hep.510260721 · Cited by 325
Corrao, G., & Aricò, S. (1998) · Hepatology · doi:10.1002/hep.510270404 · Cited by 324
Hepatitis B virus and hepatocellular carcinoma
Arbuthnot, P., & Kew, M. (2001) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2001.iep178.x · Cited by 306
Influence of MHC class II genotype on outcome of infection with hepatitis C virus
Thursz, M., Yallop, R., Goldin, R., Trepo, C., & Thomas, H. C. (1999) · The Lancet · doi:10.1016/s0140-6736(99)91443-5 · Cited by 287
Role of alcohol in the progression of liver disease caused by hepatitis C virus infection
Ostapowicz, G., Watson, K. J., Locarnini, S. A., & Desmond, P. V. (1998) · Hepatology · doi:10.1002/hep.510270637 · Cited by 286
Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children
Lai, M. E., Mazzoleni, A. P., Balestrieri, A., Argiolu, F., De Virgilis, S., Cao, A., Purcell, R. H., & Farci, P. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91224-6 · Cited by 276
Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis
Tremolada, F., Casarin, C., Alberti, A., Drago, C., Tagger, A., Ribero, M. L., & Realdi, G. (1992) · Journal of Hepatology · doi:10.1016/s0168-8278(05)80657-9 · Cited by 263
Shakil, A. O., Conry-Cantilena, C., Alter, H. J., Hayashi, P., Kleiner, D. E., Tedeschi, V., Krawczynski, K., Conjeevaram, H. S., Sallie, R., Bisceglie, A. M. D., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-5-199509010-00002 · Cited by 254
Self-citationHepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma
Kew, M. C., Houghton, M., Choo, Q. L., & Kuo, G. (1990) · The Lancet · doi:10.1016/0140-6736(90)90474-j · Cited by 253
Bellentani, S., Pozzato, G., Saccoccio, G., Crovatto, M., Crocè, L. S., Mazzoran, L., Masutti, F., Cristianini, G., & Tiribelli, C. (1999) · Gut · doi:10.1136/gut.44.6.874 · Cited by 246
Hepatitis C-associated hepatocellular carcinoma
Hasan, F., Jeffers, L. J., De Medina, M., Reddy, R. K., Parker, T., Schiff, E. R., Houghton, M., Choo, Q., & Kuo, G. (1990) · Hepatology · doi:10.1002/hep.1840120323 · Cited by 235
Non-A, Non-B Post-Transfusion Hepatitis: Looking Back in the Second Decade
Koretz, R. L., Abbey, H., Coleman, E., & Gitnick, G. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-2-199307150-00003 · Cited by 233
Gretch, D., Corey, L., Wilson, J., dela Rosa, C., Willson, R., Carithers, R., Busch, M., Hart, J., Sayers, M., & Han, J. (1994) · Journal of Infectious Diseases · doi:10.1093/infdis/169.6.1219 · Cited by 210
Seeff, L. B., Zimmerman, H. J., Wright, E. C., Finkelstein, J. D., Garcia-Pont, P., Greenlee, H. B., Dietz, A. A., Leevy, C. M., Tamburro, C. H., Schiff, E. R., et al. (1977) · Gastroenterology · doi:10.1016/s0016-5085(77)80313-2 · Cited by 200
Self-citationYu, M. C., Tong, M. J., Coursaget, P., Ross, R. K., Govindarajan, S., & Henderson, B. E. (1990) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/82.12.1038 · Cited by 175
EFFICACY OF PROPHYLACTIC GAMMA-GLOBULIN IN PREVENTING NON-A, NON-B POST-TRANSFUSION HEPATITIS
Knodell, R., Ginsberg, A., Conrad, M., Bell, C., & Flannery, E. P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)90357-3 · Cited by 174
Kato, Y., Nakata, K., Nagataki, S., Omagari, K., FURUKAWA, R., KUSUMOTO, Y., Mori, I., TAJIMA, H., Tanioka, H., & Yano, M. (1994) · Cancer · doi:10.1002/1097-0142(19941015)74:8<2234::aid-cncr2820740805>3.0.co;2-6 · Cited by 157
Björkander, J., Cunningham‐Rundles, C., Lundin, P., Olsson, R., Söderström, R., & Hanson, L. Å. (1988) · The American Journal of Medicine · doi:10.1016/0002-9343(88)90016-2 · Cited by 155
The role of chronic viral hepatitis in hepatocellular carcinoma in the United States.
Bisceglie, A. M. D., Order, S. E., Klein, J., Waggoner, J. G., Sjögren, M. H., Kuo, G. C., Houghton, M., Choo, Q. L., & Hoofnagle, J. H. (1991) · PubMed · Cited by 150
Chronic Consequences of Non-A, Non-B Hepatitis
Alter, H. J. (1989) · Springer eBooks · doi:10.1007/978-1-4684-7041-3_8 · Cited by 149
Self-citationPozzato, G., Kaneko, S., Moretti, M., Crocè, L. S., Franzin, F., Unoura, M., Bercich, L., Tiribelli, C., Crovatto, M., Santini, G., et al. (1994) · Journal of Medical Virology · doi:10.1002/jmv.1890430318 · Cited by 146
Gordon, S. C., Elloway, R. S., Long, J. C., & Dmuchowski, C. (1993) · Hepatology · doi:10.1002/hep.1840180609 · Cited by 132
Czaja, A. J., Carpenter, H. A., Santrach, P. J., & Moore, S. B. (1996) · Journal of Hepatology · doi:10.1016/s0168-8278(96)80186-3 · Cited by 116
Mattsson, L., Sönnerborg, A. B., & Weiland, O. (1993) · Liver International · doi:10.1111/j.1600-0676.1993.tb00644.x · Cited by 108
Hadziyannis, S. J., Tabor, E., Kaklamani, E., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910600510 · Cited by 85
García‐Monzón, C., Jara, P., Fernández‐Bermejo, M., Hierro, L., Frauca, E., Camarena, C., Díaz, C., Vega, A. D. L., Larrauri, J., García-Iglesias, C., et al. (1998) · Hepatology · doi:10.1002/hep.510280633 · Cited by 77
HEPATITIS C INFECTION IN TRANSPLANTATION
Pessôa, M. G., & Wright, T. L. (1997) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70328-7 · Cited by 25
Cited by
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2009) · Hepatology · doi:10.1002/hep.22759 · Cited by 2,973
Self-citationRobust hepatitis C virus infection in vitro
Zhong, J., Gastaminza, P., Cheng, G., Kapadia, S., Kato, T., Burton, D. R., Wieland, S. F., Uprichard, S. L., Wakita, T., & Chisari, F. V. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503596102 · Cited by 1,709
Highly Permissive Cell Lines for Subgenomic and Genomic Hepatitis C Virus RNA Replication
Blight, K. J., McKeating, J. A., & Rice, C. M. (2002) · Journal of Virology · doi:10.1128/jvi.76.24.13001-13014.2002 · Cited by 1,193
Course and outcome of hepatitis C
Hoofnagle, J. H. (2002) · Hepatology · doi:10.1002/hep.1840360704 · Cited by 1,084
AASLD practice guidelines: Evaluation of the patient for liver transplantation†
Murray, K. F., & Carithers, R. L. (2005) · Hepatology · doi:10.1002/hep.20704 · Cited by 939
Metadata
- Authors
- Alter, H. J., & Seeff, L. B.
- Venue
- Seminars in Liver Disease
- Publisher
- Georg Thieme Verlag KG
- Published
- 2000
- Volume
- Volume 20
- Issue
- Number 01
- Pages
- 0017-0036
- ISSN
- 0272-8087 (ISSN-L)
- 1098-8971
- OpenAlex
- W2020004919
- Cited by
- 736
- References
- 61
- FWCI
- 22.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.